Malaria is a mosquito-borne disease caused by parasites of the obligate intracellular
Apicomplexa phylum the most deadly of which, Plasmodium falciparum, prevails in Africa …

In 2013 there were an estimated 584,000 deaths and 198 million clinical illnesses due to
malaria, the majority in sub-Saharan Africa. Vaccines would be the ideal addition to the …

Vaccines activate suitable immune responses to fight against diseases but can possess
limitations such as compromised efficacy and immunogenic responses, poor stability, and …

Malaria liver stages represent an ideal therapeutic target with a bottleneck in parasite load
and reduced clinical symptoms; however, current in vitro pre-erythrocytic (PE) models for …

Malaria parasite infection is initiated by the mosquito-transmitted sporozoite stage, a highly
motile invasive cell that targets hepatocytes in the liver for infection. A promising approach to …

Immunization with live-attenuated Plasmodium sporozoites completely protects against
malaria infection. Genetic engineering offers a versatile platform to create live-attenuated …

Despite continuous efforts, the century-old goal of eradicating malaria still remains. Multiple
control interventions need to be in place simultaneously to achieve this goal. In addition to …

Malaria caused by Plasmodium vivax continues being one of the most important infectious
diseases around the world; P. vivax is the second most prevalent species and has the …

The secreted malarial protein, Cell-Traversal protein for Ookinetes and Sporozoites
(CelTOS), is highly conserved among Plasmodium species, and plays a role in the invasion …

Plasmodium vivax pre-erythrocytic (PE) vaccine research has lagged far behind efforts to
develop Plasmodium falciparum vaccines. There is a critical gap in our knowledge of PE …